Severe Congenital Cutaneous Mastocytosis with KIT D816V
Mutation in the Skin Treated with Vinblastine

Anna Zielińska; Izabela Staniszewska; Zuzanna Tomaszewska; Ksawery Szlęzak; Dorota Bulsiewicz

doi:10.5114/dr.2025.158598

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

5/2025
vol. 112

Send email

Copy url:

abstract:

Case report

Severe Congenital Cutaneous Mastocytosis with KIT D816V Mutation in the Skin Treated with Vinblastine

Anna Z. Zielińska

¹

,

Izabela Staniszewska

¹

,

Zuzanna M. Tomaszewska

¹

,

Ksawery Szlęzak

¹

,

Dorota Bulsiewicz

²

Medical University of Warsaw, Poland
Children's Memorial Health Institute, Warsaw, Poland

Dermatol Rev/Przegl Dermatol 2025, 112, 321-326

DOI: https://doi.org/10.5114/dr.2025.158598

Online publish date: 2025/12/30

View full text Get citation

PlumX metrics:

Introduction
Cutaneous mastocytosis is a skin disorder characterized by abnormal mast cell accumulation. The KIT D816V mutation plays a key role in cutaneous mastocytosis pathogenesis and limits the use of tyrosine kinase inhibitors. Early diagnosis is challenging due to its resemblance to other skin conditions.

Case report
A male newborn presented with widespread blisters, erythema, tachycardia, hypotension, and hypoxia. Despite treatment with steroids and antihistamines, symptoms persisted. Genetic testing confirmed KIT D816V mutation in the skin, excluding imatinib therapy. Other treatment options were attempted without success. Finally, vinblastine, a vinca alkaloid, was administered, leading to resolution of symptoms.

Conclusions
Molecular diagnostics are crucial for selecting appropriate treatment in cutaneous mastocytosis. Identifying patients with KIT D816V mutation helps tailor the therapy, as uncommon KIT mutations present significant therapeutic challenges. When standard treatments fail, alternative strategies such as vinblastine should be considered. This case highlights the need for individualized treatment approaches in cutaneous mastocytosis.

keywords:

newborn, mastocytosis, cutaneous mastocytosis, diffuse cutaneous mastocytosis, mast cells

Indeks osobowy

Severe Congenital Cutaneous Mastocytosis with KIT D816V Mutation in the Skin Treated with Vinblastine

Anna Z. Zielińska 1 , Izabela Staniszewska 1 , Zuzanna M. Tomaszewska 1 , Ksawery Szlęzak 1 , Dorota Bulsiewicz 2

newborn, mastocytosis, cutaneous mastocytosis, diffuse cutaneous mastocytosis, mast cells

Anna Z. Zielińska

¹

,

Izabela Staniszewska

¹

,

Zuzanna M. Tomaszewska

¹

,

Ksawery Szlęzak

¹

,

Dorota Bulsiewicz

²